Shots:The interview provided an understanding of the data from its Alzheimer’s disease pipeline at the AD/PD ConferenceThe spokespeople also talked about the clinical trial data and key mechanisms of Eisai’s anti-amyloid compound in AD The discussion showed gave a gist of four key symposium presentations that showed how its lead candidate has the…
